Data / Form D filings / CuraSen Therapeutics, Inc.
CuraSen Therapeutics, Inc.: Form D filings
CuraSen Therapeutics, Inc., a biotechnology company in San Carlos, CA, filed 5 Form D notices with the SEC between 2019 and 2024. The latest, on September 18, 2024, reports $5.8 million sold of a $45.7 million offering to 7 investors.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 733 Industrial Road, San Carlos, CA, 94070
- Phone
- (650) 475-2842
- Industry
- Biotechnology
- Entity type
- Corporation
- Incorporated in
- Delaware
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 1765883
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Sep 18, 2024 | New notice | $45,690,305 | $5,785,019 | $39,905,286 | 7 | Aug 26, 2024 | sec.gov |
| Oct 12, 2023 | Amendment | $20,814,709 | $17,599,997 | $3,214,712 | 11 | Nov 1, 2022 | sec.gov |
| Nov 10, 2022 | New notice | $14,999,997 | $14,999,997 | 10 | Nov 1, 2022 | sec.gov | |
| Nov 5, 2021 | New notice | $18,000,000 | $18,000,000 | 10 | Oct 21, 2021 | sec.gov | |
| Jan 25, 2019 | New notice | $54,499,989 | $27,249,994 | $27,249,995 | 10 | Sep 18, 2018 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Ron Sereda Hunt | Director | |
| Anthony P. Ford | Executive Officer, Director | |
| Benjamin Sereda Potter | Executive Officer | |
| Loretta Sereda Tse, Ph.D. | Director | |
| Kathleen Sereda Glaub | Director | |
| Simon Sereda Tate, Ph.D. | Director | |
| Patrick Sereda Enright | Director |
Other biotechnology companies in California that filed recently
- Trellis Bioscience, Inc. $9.1 million · Oct 29, 2026
- BigHat Biosciences, Inc. $75.1 million · Oct 26, 2026
- Theravie Pharma, Inc. $750,000 · Oct 19, 2026
- Adela, Inc. $12 million · Oct 19, 2026
- Estuary Biotherapeutics, Inc. $40.7 million · Oct 16, 2026
- Renue Life Sciences, Inc. $250,000 · Oct 14, 2026
Every Form D from the week of Sep 16, 2024 · All recent filings in California · All recent Biotechnology filings
Read from SEC EDGAR. Amount sold is what CuraSen Therapeutics, Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.